International management on approval, interchangeability and extrapolation of biosimilarsCHEN Ming-yan, XU Wei2161-2165
ICH eCTD study and recommendations for implementation in ChinaDU Jia-xi, WANG Jun-xia, YANG Yao-yao, YANG Nuo, KANG Shan-shan2166-2171
Lefamulin: a new drug for the treatment of community acquired pneumoniaZHANG De-gao, LUO Yong, JIANG Yun-da, YANG Zhong-ying2172-2177
Analysis of patent development status of anticancer drugs blocking MAPK signal pathwayZHANG Ling-ling, LI Yi2178-2184
Progress and prospect of consistency evaluation on quality and efficacy of chemical generic drugsCHEN Xin, WU Qian, WEN Bao-shu2185-2189
Investigation of reference listed drug for erythromycin enteric-coated capsule in EU and USANIU Jian-zhao, YANG Dong-sheng, MA Ling-yun, XU Ming-di2190-2193
Research progress of vardenafil in the treatment of pediatric pulmonary hypertensionJIANG Dong, ZHANG Yu-jia, ZHENG Wen-sheng2194-2199
The reasons for screening failure and dropping out of subjects in phase Ⅰ drug clinical trialsWANG Min-hui, JIA Yuan-wei, SHEN Jie, WANG Ya-qin, XIE Hai-tang2200-2204
Comparative analysis and countermeasures of clinical trial contract review between trial institutions and sponsorsCAO Ye, HE Yu, GUO Ying, YE Lin-miao, CAO Wei-zhao, HONG Ming-huang2205-2213
Prediction of therapeutic effect and targets of the main active components of Cydonia Oblanga Mill.in Xinjiang on non-small cell lung cancer based on network pharmacologyJIMILIHAN Simayi, AINIWAER Wumaier, MAIMAITIMING Nuermaimaiti, MAIERDAN Yusufu, NULIBIYA Maihemuti, MUHADAISI Nur, ZHOU Wen-ting2214-2220